KURA Overview
Upcoming Projects (KURA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KURA)
-
A third look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Tickers: SNDX, KURA
Executed On: Oct 01, 2024 at 03:00 PM EDT -
A second look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Tickers: SNDX, KURA
Executed On: Aug 22, 2024 at 05:00 PM EDT -
A look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib
Tickers: SNDX, KURA
Executed On: Aug 19, 2024 at 08:30 AM EDT -
A Second View: Discussing the KOMET-007 Trial of ziftomenib, a menin inhibitor being developed by Kura Oncology for the treatment of AML.
Ticker: KURA
Executed On: Mar 25, 2024 at 12:00 PM EDT -
Discussing the KOMET-007 Trial of ziftomenib, a menin inhibitor being developed by Kura Oncology for the treatment of AML.
Ticker: KURA
Executed On: Mar 14, 2024 at 09:00 AM EDT -
Evaluating the phase 1b clinical trial data of ziftomenib in patients with AML recently released at EHA 2023.
Ticker: KURA
Executed On: Sep 29, 2023 at 10:00 AM EDT -
A Second Look: Understanding the potential of two drugs: SNDX-5613 (revumenib) by Syndax Pharma and Ziftomenib by Kura Oncology, both being developed for treating Acute Myeloid Leukemia with recent data released at the 2022 ASH Conference.
Tickers: SNDX, KURA
Executed On: Dec 21, 2022 at 08:30 AM EST
Upcoming & Overdue Catalysts (KURA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (KURA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
